FDA's New OTC Drug Division Director Is Agency's Charles Ganley, MD
This article was originally published in The Rose Sheet
Executive Summary
The new director of FDA's OTC Drugs Division is agency insider Charles Ganley, MD. Ganley has been with the agency since 1989 when he joined as a reviewing medical officer in the Division of Cardio-Renal Drug Products. He reports to Office of Drug Evaluation V Director Robert DeLap, MD/PhD.